Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, Cortés J. O'Shaughnessy J, et al. Breast Cancer Res Treat. 2022 Sep;195(2):127-139. doi: 10.1007/s10549-022-06602-7. Epub 2022 May 11. Breast Cancer Res Treat. 2022. PMID: 35545724 Free PMC article. Clinical Trial.
Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA, Polley MY, Liu H, Gilbert JA, Cafourek V, Hillman DW, Elkhanany A, Akinhanmi M, Lilyquist J, Thomas A, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Visscher DW, Goetz MP. Leon-Ferre RA, et al. Breast Cancer Res Treat. 2018 Jan;167(1):89-99. doi: 10.1007/s10549-017-4499-7. Epub 2017 Sep 14. Breast Cancer Res Treat. 2018. PMID: 28913760 Free PMC article.
N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer.
Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. Leon-Ferre RA, et al. Breast Cancer Res Treat. 2020 Aug;182(3):613-622. doi: 10.1007/s10549-020-05709-z. Epub 2020 Jun 5. Breast Cancer Res Treat. 2020. PMID: 32504284 Free PMC article. Clinical Trial.
A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. Polley MC, et al. Breast Cancer Res Treat. 2021 Feb;185(3):557-566. doi: 10.1007/s10549-020-06030-5. Epub 2021 Jan 3. Breast Cancer Res Treat. 2021. PMID: 33389409 Free PMC article. Review.
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.
Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Carter JM, et al. Clin Cancer Res. 2021 Oct 15;27(20):5628-5637. doi: 10.1158/1078-0432.CCR-21-0343. Epub 2021 Jun 9. Clin Cancer Res. 2021. PMID: 34108182 Free PMC article.
Surveillance mammography after treatment for male breast cancer.
Yadav S, Sangaralingham L, Payne SR, Giridhar KV, Hieken TJ, Boughey JC, Mutter RW, Hawse JR, Jimenez RE, Freedman RA, Khanani S, Couch FJ, Vachon C, Shah N, Leon-Ferre RA, Ruddy KJ. Yadav S, et al. Breast Cancer Res Treat. 2022 Aug;194(3):693-698. doi: 10.1007/s10549-022-06645-w. Epub 2022 Jun 17. Breast Cancer Res Treat. 2022. PMID: 35713802
48 results